Xopenex HFA is used to treat or prevent asthma attacks in adults and children who are at least 4 years old. Xopenex HFA may also be used for purposes not listed in this medication guide.
• To maintain proper use of XOPENEX HFA, it is critical to wash the actuator with warm water and air-dry thoroughly at least once a week. The inhaler may cease to deliver levalbuterol tartrate if not properly cleaned and dried thoroughly. Keep the plastic actuator clean to prevent medication build-up and blockage.
2016 2017 2018 2019 Billable/Specific Code POA Exempt. Z79.51 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Long term (current) use of inhaled steroids. Z79.51 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM Z79.51 became effective on October 1, 2019. This is the American ICD-10-CM version of Z79.51 - other international versions of ICD-10 Z79.51 may differ.
Persons encountering health services in other specified circumstancesZ76. 89 is a valid ICD-10-CM diagnosis code meaning 'Persons encountering health services in other specified circumstances'. It is also suitable for: Persons encountering health services NOS.
ICD-10 code Z51. 81 for Encounter for therapeutic drug level monitoring is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Intestinal malabsorption, unspecifiedICD-10 code: K90. 9 Intestinal malabsorption, unspecified.
ICD-10 Code for Long term (current) use of inhaled steroids- Z79. 51- Codify by AAPC.
ICD-10-PCS GZ3ZZZZ is a specific/billable code that can be used to indicate a procedure.
Other long term (current) drug therapy The 2022 edition of ICD-10-CM Z79. 899 became effective on October 1, 2021. This is the American ICD-10-CM version of Z79.
83 – Other Fatigue. Code R53. 83 is the diagnosis code used for Other Fatigue.
ICD-10 Code for Other fatigue- R53.
5 – Low Back Pain. ICD-Code M54. 5 is a billable ICD-10 code used for healthcare diagnosis reimbursement of chronic low back pain.
The 2022 edition of ICD-10-CM Z79. 51 became effective on October 1, 2021.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes.
For treating asthma symptoms, there are three types of bronchodilators: beta-agonists, anticholinergics, and theophylline. You can get these bronchodilators as tablets, liquids, and shots, but the preferred way to take beta-agonists and anticholinergics is inhaling them.
A nutritional condition produced by a deficiency of vitamin d in the diet, insufficient production of vitamin d in the skin, inadequate absorption of vitamin d from the diet, or abnormal conversion of vitamin d to its bioactive metabolites.
Therapeutic drug monitoring (TDM) is testing that measures the amount of certain medicines in your blood. It is done to make sure the amount of medicine you are taking is both safe and effective. Most medicines can be dosed correctly without special testing.
ICD-10-CM Diagnosis Code E71 E71.
ICD-10-CM Codes that Support Medical Necessity For monitoring of patient compliance in a drug treatment program, use diagnosis code Z03. 89 as the primary diagnosis and the specific drug dependence diagnosis as the secondary diagnosis.
Levalbuterol (as tartrate) (single-isomer albuterol) 45mcg/inh; metered dose inhaler; CFC-free.
Avoid within 2 weeks of MAOIs, tricyclic antidepressants. Avoid other short-acting sympathomimetic aerosol bronchodilators, epinephrine. Antagonized by β-blockers. Caution with other drugs that may lower serum potassium (eg, diuretics). Monitor digoxin.
Accidental injury, bronchitis, dizziness, pharyngitis, rhinitis, vomiting, palpitations, chest pain, tachycardia, headache, tremor, nervousness.
Xopenex HFA is used to treat or prevent asthma attacks in adults and children who are at least 4 years old. Xopenex HFA may also be used for purposes not listed in this medication guide.
Xopenex HFA side effects. Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have: wheezing, choking, or other breathing problems after using Xopenex HFA; pounding heartbeats or fluttering in your chest;
MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, tranylcypromine, and others . Tell your doctor about all your current medicines and any you start or stop using, especially:
Before taking this medicine. You should not use Xopenex HFA if you are allergic to levalbuterol or albuterol (Accuneb, ProAir, Proventil, Ventolin ). To make sure levalbuterol is safe for you, tell your doctor if you have: a thyroid disorder.
The action of XOPENEX HFA should last for 4 to 6 hours . Do not use XOPENEX HFA more frequently than recommended. Instruct patients to not increase the dose or frequency of doses of XOPENEX HFA without consulting their physician. If patients find that treatment with XOPENEX HFA becomes less effective for symptomatic relief, symptoms become worse, or they need to use the product more frequently than usual, they should seek medical attention immediately.
In animals and humans, propellant HFA-134a was found to be rapidly absorbed and rapidly eliminated, with an elimination half-life of 3 to 27 minutes in animals and 5 to 7 minutes in humans . Time to maximum plasma concentration (tmax) and mean residence time are both extremely short, leading to a transient appearance of HFA-134a in the blood with no evidence of accumulation. Based on studies in animals, the propellant HFA-134a had no detectable toxicological activity at amounts less than 380 times the maximum human exposure based on comparisons of AUC values. The toxicological effects observed at these very high doses included ataxia, tremors, dyspnea, or salivation, similar to effects produced by the structurally-related chlorofluorocarbons (CFCs) used in metered-dose inhalers, that were extensively used in the past.
Information available in the published literature suggests that the primary enzyme responsible for the metabolism of albuterol enantiomers in humans is SULT1A3 (sulfotransferase). When racemic albuterol was administered either intravenously or via inhalation after oral charcoal administration, there was a 3- to 4-fold difference in the area under the concentration-time curves between the (R)- and (S)-albuterol enantiomers, with (S)-albuterol concentrations being consistently higher. However, without charcoal pretreatment, after either oral or inhalation administration the differences were 8- to 24-fold, suggesting that (R)-albuterol is preferentially metabolized in the gastrointestinal tract, presumably by SULT1A3.
As with other beta-adrenergic agonist medications, XOPENEX HFA may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.
XOPENEX HFA, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and symptoms. Although such effects are uncommon after administration of XOPENEX HFA at recommended doses, if they occur, the drug may need to be discontinued. In addition, betaagonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, XOPENEX HFA, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
XOPENEX HFA can produce paradoxical bronchospasm, which may be life-threatening. If paradoxical bronchospasm occurs, XOPENEX HFA should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
XOPENEX HFA is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of XOPENEX HFA. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema.